GSK, a pharmaceutical and biotechnology company, completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company, for $1.4bn. “Given the limited treatment options for asthma patients with low T2 inflammation, we look forward to using our deep respiratory expertise to potentially offer a long-acting biologic to a broader portion of the 315 million patients living with asthma,” Tony Wood, GSK Chief Scientific Office.